Account Info
Log Out
English
Back
Log in to access Online Inquiry
Back to the Top

NEWS

Veru to Deliver Keynote Presentation on the Scientific Support for Enobosarm in Combination with GLP-1 Receptor Agonist to Preserve Muscle for Higher Quality Weight Loss at the 4th Edition of the World Obesity and Weight Management Congress
Veru Inc. (NASDAQ: VERU) announced its participation in the World Obesity and Weight Management Congress, scheduled for October 24-26, 2024, in Baltimore, Maryland. The company will deliver a keynote presentation on October 25, 2024, from 9:40 AM to 10:20 AM EDT at the Best Western Plus Hotel & Conference Center.
The presentation, titled 'Advancing enobosarm, an oral novel Selective Androgen Receptor Modulator (SARM), to avoid muscle loss and augment fat loss when combined with a Glucagon-Like Peptide-1 Receptor Agonist (GLP-1 RA) drugs for potentially higher quality weight loss', will focus on the scientific support for combining enobosarm with GLP-1 receptor agonists to preserve muscle during weight loss.
Veru Inc. is a late clinical stage biopharmaceutical company developing innovative medicines for preserving muscle for high quality weight loss, oncology, and viral induced acute respiratory distress syndrome.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only. Read more
2
Translate
Report
4777 Views
Comment
Sign in to post a comment
Spread kindness and love. Life is short. Don’t let greed eat you.
2537Followers
107Following
28KVisitors
Follow